Renal cell carcinomas (RCCs) with the t(6;11)(p21;q12) chromosome translocation are low-grade RCC which often occur in young patients. They typically feature an unusual biphasic morphology characterized by nests of larger epithelioid cells surrounding intraluminal collections of smaller cells clustered around basement membrane material. The t(6;11)(p21;q12) translocation fuses the Alpha (MALAT1) gene with the TFEB transcription factor gene, resulting in upregulated expression of intact native TFEB that drives the aberrant expression of melanocytic markers which is a hallmark of this distinctive neoplasm. We now report 8 cases of RCC, which demonstrate TFEB gene amplification (6 without TFEB rearrangement, 2 with concurrent TFEB rearrangement) and demonstrate downstream consequences of TFEB overexpression. Like the unamplified t(6;11) RCC, all TFEB-amplified RCC were associated with aberrant melanocytic marker expression. However, several differences between TFEB-amplified RCC and the usual unamplified t(6;11) RCC are evident. First, TFEB-amplified RCC occurred in older patients (median age, 64.5 y) compared with unamplified t(6;11) RCC (median age, 31 y). Second, the morphology of TFEB-amplified RCC is not entirely distinctive, frequently featuring nests of high-grade epithelioid cells with eosinophilic cytoplasm associated with pseudopapillary formation and necrosis, or true papillary formations. These patterns raise the differential diagnosis of high-grade clear cell and papillary RCC. Third, TFEB and melanocytic marker expression was more variable within the TFEB-amplified RCC. TFEB protein expression by immunohistochemistry was detectable in 6 of 8 cases. While all 8 cases expressed melan-A, only 5 of 8 expressed cathepsin K and only 3 of 8 expressed HMB45. Fourth, the TFEB-amplified RCC were associated with a more aggressive clinical course; 3 of 8 cases presented with advanced stage or metastatic disease, 2 subsequently developed metastatic disease, whereas the other 3 cases had minimal/no follow-up. Our results are corroborated by scant data reported on 6 TFEB-amplified RCC in the literature, gleaned from 1 case report, 1 abstract, and 4 individual cases identified within 2 genomic studies of large cohorts of RCC. In summary, TFEB-amplified RCC represent a distinct molecular subtype of high-grade adult RCC associated with aggressive clinical behavior, variable morphology, and aberrant melanocytic marker expression.
R enal cell carcinomas (RCCs) with the t(6;11)(p21;q12) chromosome translocation were initially described in 2001. 1 In the initial description of 2 cases, the neoplasms were noted to be composed of nests of epithelioid cells with clear to eosinophilic cytoplasm associated with a subpopulation of smaller cells surrounding hyaline basement membrane material. Despite the epithelioid morphology that suggested carcinoma, these neoplasms did not label for epithelial immunohistochemical markers but instead demonstrated focal labeling for melanocytic markers HMB45 and melan-A, which raised the question of whether these neoplasms represented RCC or variants of epithelioid angiomyolipoma. With greater clinical experience and broader immunohistochemical analysis, it has become clearer that these neoplasms represent RCCs which clinically, morphologically, and immunohistochemically overlap with the Xp11 translocation RCC. [2] [3] [4] [5] [6] Although both may occur in adults, both the Xp11 translocation RCC and the t(6;11) RCC disproportionately affect young patients. Overall, the t(6;11) RCC are more indolent and metastasize less frequently than the Xp11 RCC, but both have the capacity to metastasize many years after diagnosis. Both can share common morphologic patterns including papillary architecture with clear cells, or a smaller cell population clustered around basement membrane material. Both typically express renal tubular markers like PAX8, but they underexpress cytokeratins and often express melanocytic markers and the serine protease cathepsin K. [7] [8] [9] [10] [11] Genetic evidence of a relationship between the t(6;11) RCC and the Xp11 translocation RCC was provided when the t(6;11)(p21;q12) translocation was found to fuse the Alpha (MALAT1) gene with the TFEB transcription factor gene, a gene which belongs to the same subfamily of transcription factors as TFE3 and has overlapping functional activity. 12, 13 Therefore, based upon clinical, morphologic, immunohistochemical, and genetic overlap, both the 2013 Vancouver Classification of Renal Neoplasia and 2016 World Health Organization classification group the Xp11 translocation RCC and the t(6;11) RCC under the family of MiT family translocation RCC. 14, 15 The expected consequence of the t(6;11)(p2.1;q12) translocation is overexpression of intact TFEB protein, as the breakpoint in TFEB is within intron 1, which is upstream of the ATG initiation codon. Indeed, overexpressed intact TFEB protein can be detected by immunohistochemistry as a marker for these RCC, as the native protein is expressed at low levels that are not detected. 2 Logically, other mechanisms of increased TFEB gene expression (such as gene amplification, aberrant methylation, aberrant micro-RNA expression, etc) could in theory create a similar phenotype to the t(6;11) RCC; however, such cases have not been well described in the literature.
In this report, we describe 8 adult RCCs which demonstrate TFEB amplification. In 6 cases, amplification occurred without evidence of TFEB rearrangement; whereas in the other 2, amplification and rearrangement occurred concurrently. These neoplasms demonstrated variable morphology, variable degrees of expression of melanocytic markers melan-A and HMB45 as well as cathepsin K, and more aggressive clinical behavior relative to the usual unamplified t(6;11) RCC.
MATERIALS AND METHODS

Cases
The 8 cases reported herein derive from the consultation files of the authors (PA, VER). In 5 cases, the renal neoplasms were sent specifically for assessment of TFE3 and TFEB rearrangements by fluorescence in situ hybridization (FISH) after extensive workups of otherwise unclassified RCC revealed aberrant labeling for melan-A. In 3 other cases, the renal neoplasms were sent for classification without specific suspicion of TFE3 or TFEB alterations, but TFEB FISH was performed after we found the neoplasm labelled for melan-A. TFEB amplification was detected as increased numbers of fused or split signals in the routine TFEB FISH assay used on all tumors (see below). The referring pathologists were contacted for additional clinical follow-up information.
Immunohistochemistry
Immunohistochemistry (IHC) was performed using previously described methods 16 for PAX8, cathepsin K, carbonic anhydrase 9 (CA-IX), HMB45, and melan-A. TFEB IHC was performed and scored as previously described. 2 IHC for fumarate hydratase was performed using the Santa Cruz antibody, catalog #100743, clone J-13, at 1:200 dilution with steam retrieval.
FISH Methodology
FISH on interphase nuclei from paraffin-embedded 4mm sections was performed applying custom probes using bacterial artificial chromosomes (BAC), covering and flanking TFEB gene. TFEB break-apart FISH was performed as previously described. 17 . DNA from individual BACs was isolated according to the manufacturer's instructions, labeled with different fluorochromes in a nick translation reaction, denatured, and hybridized to pretreated slides. Slides were then incubated, washed, and mounted with DAPI in an antifade solution, as previously described. 17 The genomic location of each BAC set was verified by hybridizing them to normal metaphase chromosomes. Two hundred successive nuclei were examined using a Zeiss fluorescence microscope (Zeiss Axioplan, Oberkochen, Germany), controlled by Isis 5 software (Metasystems, Newton, MA). A positive score was interpreted when at least 20% of the nuclei showed a breakapart or amplified signal. Nuclei with incomplete set of signals were omitted from the score. An amplified signal was defined as >10:1 ratio of TFEB signal to reference.
RESULTS
Cases
All of the patients in this cohort were adults, ranging in age from 23 to 77 years (mean, 62.5 y; median, 64.5 y) ( Table 1 ). There were 5 females and 3 males. Cases 1 to 6 demonstrated TFEB amplification alone, whereas cases 7 and 8 demonstrated both TFEB amplification and rearrangement. Although the case numbers are small, we did not appreciate significant clinicopathologic differences between these 2 groups (see below).
Three cases (cases 1, 6, and 7) presented at advanced stage. Case 1 was an 11 cm pT3b neoplasm which presented with renal vein involvement and regional lymph node metastases. Case 6 was a 12 cm pT3b neoplasm which presented with renal vein involvement which extended to the vein margin. Case 7 was a 19 cm pT4 neoplasm which presented with vaginal metastasis. These cases had minimal clinical follow-up, with case 1 remaining free of disease at 28 months. Two other seemingly localized neoplasms metastasized within 1 year of diagnoses. Case 2 was a small (3 cm) neoplasm treated by partial nephrectomy with microscopic capsular invasion and a microscopically positive parenchymal margin, which recurred as para-aortic lymph node metastasis after 3 months. Case 4 was a 7 cm organ-confined neoplasm which recurred as a vaginal metastasis at 8 months follow-up. Three other recent cases (cases 3, 5, and 8) were small pT1 neoplasms (1.9, 2.7, and 4.0 cm.) treated by nephrectomy on which there is no available follow-up. 4C, and 5D). In 4 cases, labeling was moderate (2+) which is considered positive; in the other 2, labeling was weak/ equivocal (1+) which is scored as negative. This level of labeling (1 to 2+) is less than the strong positive (3+) TFEB labeling which is usually seen in the nonamplified t(6;11) RCC. 2 Five of 8 cases demonstrated immunoreactivity for cathepsin K (1 diffuse, 4 patchy), which contrasts with consistently diffuse labeling seen in usual t(6;11) RCC (Figs. 3F, 4E, and 5F). In 3 of 8 cases, individual neoplastic cells labeled for HMB45, which is the typical pattern seen in the t(6;11) RCC (Fig. 4F ). All cases were at least focally immunoreactive for cytokeratin ( Fig. 1D ). Fumarate hydratase was intact in all 8 cases, whereas no case demonstrated diffuse CA-IX expression.
FISH Results
All cases included in the study showed high level amplification of TFEB, defined as greater than a 10:1 ratio of TFEB signals relative to that of surrounding normal cells (Fig. 6 ). In reality, all the cases showed hundreds of copies of TFEB in the form of homogeneous staining region or multifocal amplicons. Cases 1 to 6 demonstrated TFEB amplification alone, whereas cases 7 and 8 demonstrated both TFEB amplification and rearrangement.
Case 4 was also studied by targeted sequencing of 350 cancer-related genes using the clinical MSKCC IMPACT-assay, which confirmed the presence of TFEB gene amplification and demonstrated no evidence of mutation within TFEB.
DISCUSSION
In this report, we describe 6 RCCs which demonstrate TFEB gene amplification. There is limited information regarding neoplasms with this genetic alteration in the literature (Table 1 ). Three cases with putative TFEB gene amplification based on the GISTIC algorithm for copy number alterations were reported within the TCGA sequencing study of 291 cases originally classified as papillary RCC. One case was a 28-year-old white woman who presented with locally advanced (stage III, pT3N1) disease and showed no evidence of recurrence in only limited follow-up (4 mo). The second was a 61-year-old black woman who also presented with locally advanced (pT3aNX) disease and recurred at 14 months follow-up. 21 The third was a 59-year-old black man who presented with locally advanced disease (stage III, pT3N1), recurred at 75 months follow-up and died at 86 months. Although 1 TCGA case demonstrated a fumarate hydratase mutation, other genetic alterations of papillary RCC (ie, trisomy 7 or 17) or other defined subtypes of RCC are not evident from the published data. A single case demonstrating TFEB amplification was reported by Durinck et al 19 as a low-grade renal carcinoma with oncocytic and papillary features, but illustrations were not provided and further features were not described. Peckova et al 18 reported a case in a 77-year-old woman who demonstrated TFEB rearrangement and amplification that metastasized to the adrenal gland and lung, causing patient death 2.5 months after diagnosis. This neoplasm had nested/alveolar/pseudopapillary architecture, and was predominantly composed of high-grade polygonal eosinophilic cells similar to the majority of cases described herein. Williamson et al 20 recently reported in abstract form a single case of a pT3a RCC in a 57-year-old man associated with chromosome 6p amplification including TFEB, and referenced 2 of the TCGA cases noted above. The provided illustration demonstrates nested architecture, polygonal eosinophilic cells, and vascular invasion. Overall, TFEB amplification seems to be a relatively uncommon event; the 8 cases of TFEBamplified RCC in this study represent <10% of RCC associated with TFEB alterations in our files. Moreover, TFEB amplification was seen in only 1% of cases in the TCGA papillary RCC study referenced above. 21 All of the cases described herein showed some evidence of aberrant melanocytic marker expression which is a hallmark of the usual unamplified t(6;11) RCC, though this was variable and overall of a lesser degree. Overall, all 8 cases expressed melan-A, but only 5 of 8 cases expressed cathepsin K and only 3 of 8 cases expressed HMB45. One simple explanation for this variability would be that the level of TFEB gene amplification correlates with aberrant melanocytic marker expression. However, all cases showed hundreds of TFEB signals on FISH analysis, so this direct correlation could not be made. We do note that the 2 cases in our series in which TFEB immunoreactivity could not be detected (cases 2 and 7) were the ones with the least amount of melanocytic marker expression (melan-A labeling only), so this mechanism remains possible. The lesser melanocytic marker immunoreactivity in the 2 cases with both rearrangement and amplification relative to usual unamplified t(6;11) RCC remains difficult to explain without investigating the TFEB fusion partner and the level of TFEB mRNA expression. Along these lines, 2 of the 3 cases showing TFEB amplification in the TCGA papillary RCC study had abnormal TFEB mRNA levels suggesting that there is potential heterogeneity of TFEB expression within this family of neoplasms.
However, many differences exist between the TFEBamplified RCC reported herein and the usual unamplified t(6;11) RCC. First, the TFEB-amplified RCC occurred in a significantly older age group (median, 64.5 y; mean, 62.5 y) than the usual t(6;11) RCC (median age, 31 y; mean age, 32.8 y based on review of the literature and unpublished cases in our files) (2-sample t test = 0.0003). These findings are consistent with the median age of the few TFEB-amplified RCCs reported in the literature (59 y). Second, our cases were associated with more aggressive clinical behavior than the usual t(6;11) RCC, which generally has an indolent course. Three of our 8 cases presented with advanced disease, 2 subsequently developed metastatic disease, whereas the other 3 were small, localized pT1 lesions with minimal follow-up. Our results again corroborate prior reports, as all 3 TFEB-amplified cases included within the TCGA papillary RCC study presented with locally advanced disease (2 of which metastasized in limited follow-up), whereas the case reported by Peckova et al 18 presented as a large tumor that metastasized and caused patient death. In contrast, nonamplified t(6;11) RCC have generally had an indolent clinical course, with only 5 metastases in approximately 60 cases (including published cases and unpublished cases in our files). Third, none of our cases demonstrated the typical morphology of the t(6;11) RCC (larger cells surrounding smaller cells clustered around basement membrane material) throughout, though case 8 did show a different biphasic pattern and cases 5 and 8 showed focal areas of small and large cells. This is again consistent with the previously described cases, in which only the amplified and rearranged case reported by Peckova et al 18 was noted to show typical t(6;11) biphasic morphology, and this was noted to be less than typically seen in unamplified t(6;11) RCC. Instead, the morphology of the TFEB-amplified cases was more variable though consistently of high nucleolar grade. Most (6/8) cases demonstrated nested/pseudopapillary architecture and were composed of polygonal, epithelioid cells with prominent eosinophilic cytoplasm. Two cases demonstrated striking prominent nucleoli similar to that of the fumarate hydratase deficient HLRCC-associated RCC. 22 Other cases showed clear cells and papillary architecture (cases 2 and 4) and the distinctive biphasic pattern noted above (case 8). It seems likely that additional genetic alterations within these neoplasms which may not be shared (perhaps including variable other genes coamplified with TFEB in different cases) are responsible for the variable morphology and immunohistochemical profiles of these neoplasms.
It should be emphasized that the cases reported herein show high levels of TFEB amplification (ie, >100 copies present). This should be distinguished from cases with low levels of increased TFEB copy number. The latter may represent chromosome 6 polysomy, which is nonspecific and seen in a variety of cancers.
The association of TFEB amplification with more aggressive clinical course is intriguing given prior studies of the effects of gene amplification in MiT family cancers. Previously, Macher-Goeppinger et al 23 demonstrated that TFE3 amplification is another mechanism of TFE3 overexpression in RCC lacking TFE3 rearrangement, and found that such cases were associated with a worse prognosis. In melanoma, amplification of MiTF has been associated with poor prognosis. 24, 25 These results are intriguing given the aggressive behavior noted in TFEBamplified RCC relative to the typical indolent course of the unamplified t(6;11) RCC. Given that TFEB immunoreactivity is less in TFEB-amplified RCC than unamplified t(6;11) RCC, it seems unlikely that an increased cellular level of TFEB in the TFEB-amplified RCC relative to that in the usual t(6;11) RCC is the key reason for the aggressive behavior. Instead, it seems likely that additional concurrent genetic alterations which are as yet unknown (such as genomic instability) drive the aggressive clinical behavior.
The differential diagnosis for these TFEB-amplified RCC is broad. The nested alveolar architecture combined with eosinophilic cytoplasm and prominent nucleoli raises the differential diagnosis of the most common RCC, conventional clear cell RCC, which frequently has eosinophilic cytoplasm when it is high grade.
The absence of diffuse CA-IX immunoreactivity in any of the TFEB-amplified RCC argues against this differential diagnosis, as does the melanocytic marker expression noted. Given that the TFEB-amplified RCC appear to behave aggressively, it is likely that such cases might be encountered in the limited material of a biopsy of a metastatic site in a patient with a renal mass. Particularly in this setting, such cases could easily be misclassified as "consistent with high grade clear cell RCC," given that CA-IX labeling tends to be diminished in high-grade clear cell RCC and melanocytic markers are usually not performed when such material is limited. The pseudopapillary growth pattern noted in 6 cases and the papillary architecture noted in 2 cases raises the differential diagnosis of high-grade papillary RCC. Indeed, as noted previously, 3 apparent TFEB-amplified RCC were included in the TCGA study of papillary RCC, 21 further highlighting the genetic heterogeneity of RCC with papillary architecture and high-grade nuclei. As above, small samples of such RCC in metastatic sites could easily be interpreted as "consistent with high grade papillary RCC" unless a melan-A stain were performed. The prominent nucleoli raise the possibility of HLRCCassociated RCC, but the intact fumarate hydratase and aberrant melan-A expression argues against this possibility.
In summary, we report herein 8 adult RCC associated with TFEB amplification. Although the morphology is variable, the tumors were all high grade and all showed some evidence of aberrant melanocytic marker expression similar to that typically seen in unamplified t(6;11) RCC, though this was more variable and inconsistent among these tumors. TFEB-amplified RCC overall have a more aggressive clinical course in this limited series than do the usual unamplified t(6;11) RCC, which overexpress TFEB only as a result of a chromosome translocation. Nonetheless, as all of these were consultation cases (which creates potential bias compared with unselected cases) and the numbers are relatively small, further studies of these unusual cancers are needed to better define their clinical and pathologic features.
